Avandia and the need for more transparency
This article was originally published in Scrip
Later this month we will learn whether the US and EU regulators want GlaxoSmithKline's diabetes drug Avandia off the market because of concerns over its cardiovascular safety profile.
You may also be interested in...
Health activists are stepping up the pressure on COVID-19 vaccine companies to share their IP and reveal their costs, while the European Medicines Agency has published regulatory guidance advising vaccine developers to aim for a point estimate of efficacy of at least 50%.
The EU has ambitious plans for dealing with future health crises, bolstering needs-led innovation, improving access to medicines, and tackling drug shortages.
In its latest communication to medical product companies, the DHSC says the biggest potential cause of disruption to supplies could be failure to prepare for border controls implemented by the EU member states after the end of the Brexit transition period.